Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An investigational autologous cellular therapy consisting of mesenchymal stem cells (MSCs) harvested from a patient's own bone marrow and expanded for therapeutic use. Developed by the VA Office of Research and Development, this therapy is being evaluated in a Phase 1 pilot crossover study (NCT05925036) for the treatment of pain associated with chronic pancreatitis, specifically in Veterans. The MSCs are intended to exert anti-inflammatory and immunomodulatory effects by secreting bioactive molecules that reduce pancreatic inflammation and fibrosis, potentially aiding in tissue repair and pain reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (VA Office of Research & Development).